A new paper from the SHARP Clinical Research Collaboration has been recently published in The Lancet Respiratory Medicine.
Entitled “Severe asthma and remission prospects in Europe (SHARP): insights from a multicentre observational study based on the European Severe Asthma Registry”, the study analyses data from 13,455 adults with severe asthma from 22 countries to evaluate disease burden and remission-related clinical domains in real-world practice.
Key findings include:
- Despite 79% of patients receiving biologic therapy, most continued to have active disease, with persistent airflow limitation, poor asthma control, frequent exacerbations and/or maintenance oral corticosteroid use, demonstrating that biologic treatment alone does not necessarily translate into clinical remission.
- Persistent type 2 inflammation remained common despite advanced therapies, while a subgroup of biologic-naïve patients accumulated multiple adverse disease domains within less than 10 years, suggesting a rapid disease progression trajectory and highlighting the importance of earlier intervention.
- These findings redefine remission as a multidimensional treatment goal and support earlier identification of high-risk patients, timely referral to specialist severe asthma centres and more personalised management strategies.
Read the full paper
Read the lay summary
